New Head and Neck Malignancies Innovation  Group launched
Randy Carney (left) and Andrew Birkeland (right) are
leading the new Head and Neck Malignancies
Innovation Group.

36 biomedical engineers, scientists and clinicians team up to find treatment options for these often-debilitating cancers.

It takes an army to take on cancer. In the case of the new Head and Neck Malignancies Innovation Group, it is taking a large multidisciplinary team of biomedical engineers, scientists, oncologists and veterinarians attacking the complex types of cancer from every angle. 

The group is being led by Andrew Birkeland, a head and neck oncology surgeon based at the medical campus in Sacramento, and Randy Carney, a professor of biomedical engineering on the university’s Davis campus.

“We saw a need to bring together scientists and clinicians to find novel ideas to research very unique but frustrating cancers of the head and neck that can leave survivors with severe quality of life issues,” Birkeland said. “We need advanced treatments that are more effective and are less debilitating.”

Treatment for cancers of the head and neck can leave patients with profound swallowing disorders or the inability to speak. It can also change the way a patient looks and breathes.

“Helping these patients not only survive, but thrive is a priority,” Birkeland said.

The Head and Neck Malignancies Innovation Group meets monthly on a virtual platform. Members also get together separately in teams to develop breakthroughs they can move from the laboratory to clinical trials and then to patient bedsides.

“Think of it as a ‘meeting of the minds’ as we brainstorm outside of the box on new angles to research new treatments,” said Carney, who added that the collaboration between the two campuses is critically important.

The group’s leaders also include internationally renowned head and neck cancer researcher Xiao-Jing Wang, who brought with her the first-ever Specialized Programs of Research Excellence grant from the National Cancer Institute when she joined UC Davis in 2022. The prestigious five-year $9.8 million federal grant is intended to translate cancer research into clinical interventions.


Head and neck cancer

Head and neck cancer includes tumors that develop in or around the throat, larynx (voice box), nose, sinuses or mouth. It is more common in men than women. The American Association for Cancer Research estimates this year more than 66,000 Americans will be diagnosed with head and neck cancer, which makes up about 4% of all cancers in the U.S.

Risk factors:

  • Alcohol use
  • Tobacco use
  • Human papillomavirus (HPV)
  • Oral health
  • Genetics

Symptoms:

  • Difficulty swallowing
  • Persistent lump in neck or mouth sores
  • Persistent sore throat
  • Hoarseness or voice changes

Prevention:

  • Avoid tobacco
  • Limit alcohol
  • HPV vaccination

Treatments

Head and neck cancer treatment can include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of treatments. The treatment plan for an individual patient depends on a number of factors, including the location of the tumor, the stage of the cancer, and the person’s age and general health.